RBC Capital Maintains Axonics(AXNX.US) With Hold Rating, Maintains Target Price $71
Axonics Modulation Technologies (AXNX) Receives a Hold From RBC Capital
Piper Sandler Maintains Axonics(AXNX.US) With Hold Rating, Maintains Target Price $71
Axonics Analyst Ratings
Needham Maintains Axonics(AXNX.US) With Hold Rating
Hold Rating on Axonics Modulation Technologies Amidst Slowing Growth and Pending Acquisition
RBC Capital Maintains Axonics(AXNX.US) With Hold Rating, Maintains Target Price $71
RBC Capital Remains a Hold on Axonics Modulation Technologies (AXNX)
Axonics Analyst Ratings
Needham: Reiterates that Axonics (AXNX.US) holds the rating.
Analysts Offer Insights on Healthcare Companies: 10x Genomics (TXG), Axonics Modulation Technologies (AXNX) and Eli Lilly & Co (LLY)
Wells Fargo Sticks to Its Hold Rating for Axonics Modulation Technologies (AXNX)
RBC Capital Remains a Hold on Axonics Modulation Technologies (AXNX)
Axonics Modulation Technologies (AXNX) Gets a Hold From Wells Fargo
Axonics Modulation Technologies (AXNX) Gets a Hold From Wells Fargo
Axonics Modulation Technologies (AXNX) Receives a Hold From Wells Fargo
Axonics Analyst Ratings
Truist Securities Downgrades Axonics to Hold, Lowers Price Target to $71
Axonics Analyst Ratings
Analysts' Opinions Are Mixed on These Healthcare Stocks: Axonics Modulation Technologies (AXNX) and Siemens Healthineers AG (OtherSEMHF)